← Trials/Trial dossier/NCT07001553

GLaD

Completed

Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study

Understanding the Dietary Adjustments Following GLP-1 Agonist Treatment: The GLaD Feasibility Study

Lead sponsor

Australian Catholic University

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Feasibility of recruitment

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07001553

Org study ID2025-4090H

Timeline

Milestones

Study start2025-05-28actual

Study first posted2025-06-03actual

Primary completion2026-01-07actual

Study completion2026-01-07actual

Last update posted2026-03-02actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Individuals living in Australia who are intending to commence a GLP-1 prescription

Inclusion criteria

•Aged 18+ years old

•Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months

•The primary reason for commencing the medication will be for diabetes or weight management

•Willing to participate in dietary recall and questionnaires

Exclusion criteria

•Aged under 18 years,

•used a GLP-1 agonist medication in the previous 6 months,

•unwilling or unable to provide dietary recalls

•non-English speaking.

Endpoints (21)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL

Other (unclassified)

Other clinical outcomes

Safety / tolerability / PK

Patient-reported / QoL

9 endpoints

Other/protocol endpoint

Patient perspectives

Time frame:3 months

descriptive

Other/protocol endpoint

Retrospective subjective appetite

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Other/protocol endpoint

Treatment self-regulation

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Other/protocol endpoint

Food cravings

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Other/protocol endpoint

Internalisation of weight bias

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Other/protocol endpoint

Intuitive eating

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Other/protocol endpoint

Health-related quality of life

Time frame:baseline, 1 month, 3 months

SF-36 total

change from baseline, improvement

Other/protocol endpoint

Well being

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Other/protocol endpoint

Disordered eating behaviours

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Medication symptomology

Time frame:baseline, 1 month, 3 months

descriptive

Other clinical outcomes

4 endpoints

Other/protocol endpoint

Diet quality

Time frame:baseline, 2 weeks, 1 month, 3 months

descriptive, improvement

Other/protocol endpoint/low confidence

Binge eating

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Other/protocol endpoint

Physical activity

Time frame:baseline, 1 month, 3 months

change from baseline, improvement

Other/protocol endpoint/low confidence

Dietary changes

Time frame:baseline, 3 months

descriptive

Other (unclassified)

7 endpoints

Primary/protocol endpoint

Feasibility of recruitment

Time frame:4 months

descriptive

Secondary/protocol endpoint/low confidence

Energy intake

Time frame:baseline, 2 weeks, 1 month, 3 months

descriptive

Secondary/protocol endpoint/low confidence

Medication use

Time frame:baseline, 1 month, 3 months

descriptive

Other/protocol endpoint/low confidence

Macronutrient intake

Time frame:baseline, 2 weeks, 1 month, 3 months

descriptive

Other/protocol endpoint/low confidence

Meal timing

Time frame:baseline, 2 weeks, 1 month, 3 months

descriptive

Other/protocol endpoint/low confidence

Medication use

Time frame:baseline, 1 month, 3 months

descriptive

Other/protocol endpoint/low confidence

Micronutrient intake

Time frame:baseline, 2 weeks, 1 month, 3 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.